R. Woessner

M. Mattern, C. Mirabelli, R. Johnson, 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

J. Nemunaitis, R. Kurzrock, M. Jo, 2018, Journal of Immunotherapy for Cancer.

Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.

J. E. Robinson, J. Lyssikatos, R. K. DeLisle, 2014, ACS medicinal chemistry letters.

Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations

T. Waldmann, W. Xiao, E. Jaffe, 2017, Proceedings of the National Academy of Sciences.

162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations

B. Tunquist, J. Garrus, R. Woessner, 2010 .

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1

N. Grimster, A. Åstrand, Magnus Nilsson, 2017, Expert opinion on therapeutic patents.

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

G. Mills, Z. Ju, Nidhi Sahni, 2018, Nature Communications.

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Z. Cooper, A. Waage, A. Sundan, 2020, Journal for immunotherapy of cancer.

Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.

C. Chuaqui, A. Ferguson, P. Lyne, 2018, Journal of medicinal chemistry.

STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Mingchao Xie, S. Barry, J. Barrett, 2020, Clinical Cancer Research.

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Ayşegül Özen, N. Brooijmans, T. Guzi, 2022, Journal of medicinal chemistry.

The effect of lithium on the membrane molecular dynamics of normal human erythrocytes

N. Minshew, J. Pettegrew, D. McKeag, 1987, Biological Psychiatry.

Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC

S. Schalm, R. Woessner, Clare Medendorp, 2022, Cancer Research.

Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robustin vivoantitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

K. Hoeflich, S. Lim, B. Cho, 2021, Experimental and Molecular Therapeutics.

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

S. Kazmirski, Ayşegül Özen, K. Hoeflich, 2021, Experimental and Molecular Therapeutics.

Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205

C. Chuaqui, P. Lyne, N. Grimster, 2017 .

Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization.

U. Sarkar, R. Woessner, Kelly Goodwin, 2019, Analytical biochemistry.

Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma

Nicolas Stransky, K. Hoeflich, C. Lengauer, 2022, bioRxiv.

Discovery of pyrrolopyrimidine inhibitors of Akt.

Tyler T. Risom, S. Gross, J. Blake, 2010, Bioorganic & medicinal chemistry letters.

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

S. Gross, J. Lyssikatos, K. Koch, 2010 .

Abstract 2514: ARRY-162, A Potent and Selective MEK 1/2 Inhibitor, Shows Enhanced Efficacy in Combination with Other Targeted Kinase Inhibitors and with Chemotherapy

R. Woessner, J. Winkler, Deborah H. Anderson, 2010 .

368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor

S. Cartlidge, R. Woessner, T. Klinowska, 2004 .

Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731).

A. Bitonti, T. Bush, P. Wright, 1997, Oncology research.

Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826).

R. Hoffman, Z. An, R. Woessner, 2000, Anticancer Research.

Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression

James D. Clarke, M. Congreve, J. Mason, 2017 .

Combination of the KSP Inhibitor ARRY-520 with Bortezomib or Revlimid Causes Sustained Tumor Regressions and Significantly Increased Time to Regrowth in Models of Multiple Myeloma.

B. Tunquist, D. Walker, R. Woessner, 2009 .

447 POSTER ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma

B. Tunquist, D. Trawick, D. Walker, 2008 .

Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity

C. Thiele, V. Veschi, R. Woessner, 2016, Clinical Cancer Research.

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

S. Gross, J. Lyssikatos, K. Koch, 2010 .

ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2

T. Morales, J. Lyssikatos, George T. Topalov, 2005 .